Literature DB >> 12089663

Generation and characterization of a protective monoclonal antibody to Pseudomonas aeruginosa PcrV.

Dara W Frank1, Amy Vallis, Jeanine P Wiener-Kronish, Arup Roy-Burman, Edward G Spack, Brian P Mullaney, Mehdi Megdoud, James D Marks, Robert Fritz, Teiji Sawa.   

Abstract

Pseudomonas aeruginosa is a gram-negative pathogen causing life-threatening infections. Lung injury and the development of sepsis depend largely on the expression of type III secretion system (TTSS) virulence. TTSS functions as a molecular syringe to deliver toxins directly to the cytosol of cells, inhibit innate immune mechanisms, and prevent bacterial clearance. Polyclonal antibodies that bind to PcrV of P. aeruginosa inhibit the delivery of type III toxins and enhance the clearance of bacteria during acute lung infections. PcrV is a homologue of LcrV, a protective antigen in the Yersinia TTSS and an integral component of TTSS. In this study, a murine monoclonal antibody (MAb) to PcrV was generated: MAb 166, which is protective against P. aeruginosa when coinstilled with the bacterial inoculum or intraperitoneally transferred to mice. Fab fragments from MAb 166 prevent sepsis and death. The epitope bound by MAb 166 was mapped to the carboxyl-terminus of PcrV.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12089663     DOI: 10.1086/341069

Source DB:  PubMed          Journal:  J Infect Dis        ISSN: 0022-1899            Impact factor:   5.226


  65 in total

1.  Synergistic protection of mice against plague with monoclonal antibodies specific for the F1 and V antigens of Yersinia pestis.

Authors:  Jim Hill; Catherine Copse; Sophie Leary; Anthony J Stagg; E Diane Williamson; Richard W Titball
Journal:  Infect Immun       Date:  2003-04       Impact factor: 3.441

2.  Protein binding between PcrG-PcrV and PcrH-PopB/PopD encoded by the pcrGVH-popBD operon of the Pseudomonas aeruginosa type III secretion system.

Authors:  Leonard R Allmond; Timur J Karaca; Vinh N Nguyen; Thong Nguyen; Jeanine P Wiener-Kronish; Teiji Sawa
Journal:  Infect Immun       Date:  2003-04       Impact factor: 3.441

Review 3.  Sequencing of the Pseudomonas aeruginosa and Burkholderia cepacia genomes and their applications in relation to cystic fibrosis.

Authors:  Deborah A Miller; Eshwar Mahenthiralingam
Journal:  J R Soc Med       Date:  2003       Impact factor: 5.344

4.  V-antigen genotype and phenotype analyses of clinical isolates of Pseudomonas aeruginosa.

Authors:  Leonard R Allmond; Temitayo Ajayi; Kiyoshi Moriyama; Jeanine P Wiener-Kronish; Teiji Sawa
Journal:  J Clin Microbiol       Date:  2004-08       Impact factor: 5.948

5.  Ubiquitin and ubiquitin-modified proteins activate the Pseudomonas aeruginosa T3SS cytotoxin, ExoU.

Authors:  David M Anderson; Katherine M Schmalzer; Hiromi Sato; Monika Casey; Scott S Terhune; Arthur L Haas; Jimmy B Feix; Dara W Frank
Journal:  Mol Microbiol       Date:  2011-11-21       Impact factor: 3.501

Review 6.  Surface organelles assembled by secretion systems of Gram-negative bacteria: diversity in structure and function.

Authors:  David G Thanassi; James B Bliska; Peter J Christie
Journal:  FEMS Microbiol Rev       Date:  2012-05-24       Impact factor: 16.408

7.  ExsE, a secreted regulator of type III secretion genes in Pseudomonas aeruginosa.

Authors:  Arne Rietsch; Isabelle Vallet-Gely; Simon L Dove; John J Mekalanos
Journal:  Proc Natl Acad Sci U S A       Date:  2005-05-23       Impact factor: 11.205

8.  Anti-PcrV antibody strategies against virulent Pseudomonas aeruginosa.

Authors:  Teiji Sawa; Emi Ito; Vinh Huu Nguyen; Matthew Haight
Journal:  Hum Vaccin Immunother       Date:  2014       Impact factor: 3.452

Review 9.  Progress towards recombinant anti-infective antibodies.

Authors:  Jennifer C Pai; Jamie N Sutherland; Jennifer A Maynard
Journal:  Recent Pat Antiinfect Drug Discov       Date:  2009-01

10.  Mutations in the Pseudomonas aeruginosa needle protein gene pscF confer resistance to phenoxyacetamide inhibitors of the type III secretion system.

Authors:  Nicholas O Bowlin; John D Williams; Claire A Knoten; Matthew C Torhan; Tommy F Tashjian; Bing Li; Daniel Aiello; Joan Mecsas; Alan R Hauser; Norton P Peet; Terry L Bowlin; Donald T Moir
Journal:  Antimicrob Agents Chemother       Date:  2014-01-27       Impact factor: 5.191

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.